# Zoetis **Source:** https://geo.sig.ai/brands/zoetis **Vertical:** Healthcare Tech **Subcategory:** Animal Health **Tier:** Leader **Website:** zoetis.com **Last Updated:** 2026-04-14 ## Summary Zoetis (ZTS) reported ~$9.1B revenue in FY2024. World's largest animal health company developing medicines, vaccines, and diagnostics for companion animals and livestock. HQ: Parsippany, NJ. ## Company Overview Zoetis Inc. is the world's largest animal health company, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and other technologies for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). Spun off from Pfizer in 2013, Zoetis has maintained its position as the global leader in animal health with approximately 300 product lines serving veterinarians, livestock producers, and pet owners in over 100 countries. Zoetis reported approximately $9.1 billion in revenue in FY2024, with companion animals representing roughly 55% of revenue and growing faster than the livestock segment. The shift toward companion animals reflects a powerful cultural and demographic trend: pet ownership is increasing globally, pets are increasingly viewed as family members, and spending per pet is rising as veterinary capabilities advance and pet insurance adoption grows. Zoetis's blockbuster portfolio includes Apoquel and Cytopoint (atopic dermatitis treatments for dogs), Simparica Trio (parasite protection), and Librela/Solensia (monoclonal antibodies for osteoarthritis pain in dogs and cats). The monoclonal antibody franchise represents Zoetis's most significant innovation: Librela (bedinvetmab) is the first approved monoclonal antibody for pain management in dogs with osteoarthritis, addressing an enormous unmet need in companion animals. These biologics are protected by complex manufacturing processes and intellectual property, creating durable competitive advantages. The livestock segment provides steady cash flows from parasiticides, antibiotics, and vaccines, while the companion animal segment drives premium growth through innovative specialty products. ## Frequently Asked Questions ### What does Zoetis make? Zoetis makes medicines, vaccines, and diagnostics for companion animals (dogs, cats, horses) and livestock (cattle, pigs, poultry). Key products include Apoquel/Cytopoint for dog allergies, Simparica Trio for parasites, and Librela for dog osteoarthritis pain. ### What is Librela? Librela (bedinvetmab) is Zoetis's monoclonal antibody approved for treating osteoarthritis pain in dogs — the first biologic pain medication for veterinary use. It addresses a massive unmet need in the ~80M U.S. pet dog population and is growing rapidly since its 2023 U.S. launch. ### What is Zoetis' ticker? Zoetis trades on the NYSE under the ticker ZTS. It was spun off from Pfizer in 2013 and has significantly outperformed the broader market since its IPO. ### Why is companion animal health growing faster than livestock? Pet ownership is growing globally and pet humanization trends drive higher spending per animal. Veterinary capabilities have advanced dramatically — MRIs, chemotherapy, specialty drugs for dogs — and pet insurance adoption is expanding the addressable market for premium treatments. ### What is Zoetis's approach to vaccine development for livestock and companion animals? Zoetis develops vaccines for both livestock (cattle, swine, poultry) to protect food supply health and productivity, and companion animals (dogs, cats) for viral, bacterial, and parasitic diseases. Zoetis is the only company with vaccine development capabilities across such a broad range of animal species. Its mRNA veterinary vaccine platform — developed using similar technology to human COVID mRNA vaccines — positions Zoetis to rapidly develop new animal vaccines for emerging infectious diseases. ### How large is the animal health market and what are its growth drivers? The global animal health market is approximately $65B annually and growing 6-8% per year. Growth is driven by pet humanization (owners spending more on veterinary care), protein demand growth requiring healthier livestock, expanding pet ownership in emerging markets, and innovation in biologics and diagnostics. Zoetis captures approximately 30% of the companion animal market and 20%+ of livestock health — making it the dominant global animal health company. ### What is Zoetis's pipeline beyond Librela and Apoquel? Zoetis's pipeline includes Solensia (bedinvetmab for cat osteoarthritis — the cat version of Librela), next-generation parasiticides for resistance management, mRNA-based vaccines for swine and poultry diseases, and diagnostics platforms integrated with Zoetis's treatment products. The company invests approximately 8-10% of revenue in R&D annually, focusing on the companion animal biologics that generate the highest margins and the livestock vaccines that protect global food supply chains. ### How does Zoetis compete with Merck Animal Health, Elanco, and Boehringer Ingelheim? Zoetis is the global market leader in animal health with approximately 2x the revenue of its nearest competitor. Merck Animal Health (Bravecto, Clynav), Elanco (acquired Bayer Animal Health), and Boehringer Ingelheim (acquired Merial) are the primary competitors. Zoetis differentiates on R&D productivity (several best-in-class products across multiple species), its exclusive companion animal focus before the spun-off livestock business, and commercial execution through the largest veterinary sales force in the industry. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*